Beyondspring ( (BYSI) ) has released its Q1 earnings. Here is a breakdown of the information Beyondspring presented to its investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapeutics, with its lead product, Plinabulin, in late-stage clinical development for various cancer indications. In its first-quarter 2025 earnings report, BeyondSpring highlighted significant progress in its clinical programs and provided a corporate update. The company reported early efficacy of Plinabulin combinations in treating metastatic NSCLC and Hodgkin lymphoma resistant to PD-1/L1 therapy, and SEED’s RBM39 degrader showed promising results in Ewing Sarcoma models, with an IND filing expected mid-2025. Financially, BeyondSpring reported a net income of $1.17 million for the quarter, a notable improvement from a loss in the previous year, driven by gains from discontinued operations. The company’s R&D and G&A expenses increased by 21% and 30%, respectively, reflecting ongoing investment in its development pipeline. Looking ahead, BeyondSpring remains focused on advancing its clinical programs and exploring larger indications, with strategic collaborations supporting its mission to develop transformative therapies.